Long-Term Benefit of Myectomy and Anterior Mitral Leaflet Extension in Obstructive Hypertrophic Cardiomyopathy

Severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HC) may benefit from surgical myectomy. In patients with enlarged mitral leaflets and mitral regurgitation, myectomy can be combined with anterior mitral leaflet extension (AMLE) to stiffen the midsegment of the leaflet. The aim of this study was to evaluate the long-term results of myectomy combined with AMLE in patients with obstructive HC. This prospective, observational, single-center cohort study included 98 patients (49 +/- 14 years, 37% female) who underwent myectomy combined with AMLE from 1991 to 2012. End points included all-cause mortality and change in clinical and echocardiographic characteristics. Mortality was compared with age- and gender-matched patients with nonobstructive HC and subjects from the general population. Long-term follow-up was 8.3 +/- 6.1 years. There was no operative mortality, and New York Heart Association class was reduced from 2.8 +/- 0.5 to 1.3 +/- 0.5 (p <0.001), left ventricular outflow tract gradient from 93 +/- 25 to 9 +/- 8 mm Hg (p <0.001), mitral valve regurgitation from grade 2.0 +/- 0.9 to 0.5 +/- 0.8 (p <0.001), and systolic anterior motion of the mitral valve from grade 2.4 +/- 0.9 to 0.1 +/- 0.3 (p <0.001). The 1-, 5-, 10-, and 15-year cumulative survival rates were 98%, 92%, 86%, and 83%, respectively, and did not differ from the general population (99%, 97%, 92%, and 85%, respectively, p = 0.3) or patients with nonobstructive HC (98%, 97%, 88%, and 83%, respectively, p = 0.8). In conclusion, in selected patients with obstructive HC, myectomy combined with AMLE is a low-risk surgical procedure. It results in long-term symptom relief and survival similar to the general population. (c) 2015 Elsevier Inc. All rights reserved.